Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
48 Cards in this Set
- Front
- Back
|
Carmustine |
Alkylating Agent MOA: Transfer Alkyl group to DNA - guanine. Crosslinks DNA --> miscoding, depurination, strand breaks. Checkpoint proteins in cell division recognize and initiate apoptosis |
|
|
Lomustine |
Alkylating Agent MOA: Transfer Alkyl group to DNA - guanine. Crosslinks DNA --> miscoding, depurination, strand breaks. Checkpoint proteins in cell division recognize and initiate apoptosis |
|
|
Busulfan |
Alkylating Agent MOA: Transfer Alkyl group to DNA - guanine. Crosslinks DNA --> miscoding, depurination, strand breaks. Checkpoint proteins in cell division recognize and initiate apoptosis AE: Pulmonary FIbrosis, Hepatotixicity, |
|
|
Cyclophosphamide |
Bischloroethylamine alkylating agent Alkylating Agent MOA: Transfer Alkyl group to DNA - guanine. Crosslinks DNA --> miscoding, depurination, strand breaks. Checkpoint proteins in cell division recognize and initiate apoptosis Activated in liver - acrolein is cytotoxic metabolite. leads to hemorrhagic cystitis. Hepatotoxicity. Mesna reacts to inactivate. Tx: NHL, Ovarian, Breast, Neuroblastoma |
|
|
Carmustine BCNU |
Nitrosurea Alkylating agent Alkylation at guanine -> DNA crosslink, lipid soluble |
|
|
Lomustine CCNU |
Nitrosurea Alkylating agent Alkylation at Guanine -> DNA crosslink. Lipid Soluble |
|
|
Procarbazine |
Alkylating Agent MOA: Inhibits DNA/RNA synthesis AE: BM suppression, Pulmonary Toxicity, Neurotoxicit, Leukemogenic, Teratogenic |
|
|
Cisplatin |
Platinum Analog MOA: complex to DNA --> crosslinks -->Cytotoxic AE: nephrotoxic, ototoxic (neurotox) Tx: Testicular, Ovarian, Bladder, Lung |
|
|
Carboplatin |
Platinum Analog 2nd gen MOA: DNA crosslinks AE: Myelosuppression Tx: testicular, Ovarian, Bladder, Lung |
|
|
Methotrexate |
Anti-metabolite MOA: Folic acid antagonist. Dihydrofolate reductase, prevents thymidine synthesis. doesn't cross BBB. AE: Mucositis, BM suppression, Effects prevented by leucovorin. nephrotoxic Tx: Leukemia, Lymphoma, Breast |
|
|
6 Mercaptopurine |
Purine Anatgonist MOA: converted by HGPRT to active form. inhibits enzymes for DNA/RNA synthesis. incorporation of thiopurine nucleotides AE: Myelosuppression, hepatotoxicity, don't use with allopurinol. Tx: ALL |
|
|
6 Thioguanine |
Purine Anatgonist MOA: converted by HGPRT to active form. inhibits enzymes for DNA/RNA synthesis. incorporation of thiopurine nucleotides AE: Myelosuppression, hepatotoxicity |
|
|
Fludarabine |
Purine Anatogonist MOA: Posphorylated to triphosphate. Inhibits DNApolymerase a and b. Incorporated into DNA to inhibit synthesis and function. |
|
|
5 FlouroUracil |
Prymidine Antagonist MOA: Prodrug - 5dUMP- complex with thymidylate synthetase and reduced folate to decrease thymidine. Leucovorin administration stabilizes the complex. Incorporated into DNA/RNA AE: N/D, mucositis, BM depression, alopecia Tx: Breast, Ovarian, Head/Neck Cancers |
|
|
Capecitabine |
Primidine antagonist MOA: Prodrug - 5FU conversion in tumor by thymidine phosphorylase. Decreased thymidine synthesis. Incorporation into DNA/RNA. |
|
|
Cytarabine |
Pyrimidine antagonist MOA: S phase specific, limited to hem malignancy. must be phosphorylated. INhibits DNA pol a/b to decrease repair/synthesis. Incorporation inhibits elongation. Tx: AML |
|
|
Gemcitabine |
Pyrimidine antagonist MOA: dCTP analog, inhibition of rubonucleotide reductase to decrease nucleotides for transcription. DNA termination if incorporated. |
|
|
Vinblastine |
Plant alkaloids MOA: Inhibits tubulin polymeriztation. binds b tubulin to prevent interaction with a tubulin. division arrested in metaphase. AE: myelosuppression, GI problems Tx: Hodgkins, NHL, Breast, Testicular |
|
|
Vinocristine |
Plant alkaloids MOA: Inhibits tubulin polymeriztation. binds b tubulin to prevent interaction with a tubulin. division arrested in metaphase. AE: Limited myelosuppression, Neurotoxic, Tx: ALL, Hodgkins, Leukemia, Wilms |
|
|
Vinorelbine |
Plant alkaloids MOA: Inhibits tubulin polymeriztation. binds b tubulin to prevent interaction with a tubulin. division arrested in metaphase. AE: Granulocytopenia, low neurotoxicity, |
|
|
Paclitaxel |
Taxane MOA: Bind to B tubulin to promote atypical microtubule formation --> arrested mitosis AE: myelosuppression, cumulative neurotox, hypersensitivity |
|
|
Docetaxel |
Taxane MOA: Bind to B tubulin to promote atypical microtubule formation --> arrested mitosis Resistance: P glycoprotien, B tubulin mutation AE: myelosuppression, cumulative neurotox, hypersensitivity |
|
|
Elpopaside |
Plant Alkaloid MOA: Inhibits DNA topoisomerase II --> DNA breaks and blocks division in S-G2 phase |
|
|
Teniposide |
Plant Alkaloid MOA: Inhibits DNA topoisomerase II --> DNA breaks and blocks division in S-G2 phase |
|
|
Topotecan |
Camptothecins - plant alkaloid MOA: Inhibits Topoisomerase I. stabilize strand breaks and prevents ligation |
|
|
Irinotecan |
Camptothecins - plant alkaloid MOA: Inhibits Topoisomerase I. stabilize strand breaks and prevents ligation - prodrug |
|
|
Doxorubicin |
Antitumor Abx - anthracyclines MOA: Inserts between base pairs to disrupt fx. Inhibition of Topoisomerase II to break DNA, generation of superoxide radicals AE: Myelosuppression, Cardiotoxicity, |
|
|
Daurorubicin |
Antitumor Abx - anthracyclines MOA: Inserts between base pairs to disrupt fx. Inhibition of Topoisomerase II to break DNA, generation of superoxide radicals AE: Myelosuppression, Cardiotoxicity, |
|
|
Mitoxantrone |
Antitumor Abx - anthracyclines MOA: Inserts between base pairs to disrupt fx. Inhibition of Topoisomerase II to break DNA, generation of superoxide radicals AE: Myelosuppression, minimal Cardiotoxicity, |
|
|
Bleomycin |
Antitumor Abx- specific MOA: Bifunctional binds DNA and Chelates iron. Oxidation of DNA, stops cell cycle at G2 AE: pulmonary fibrosis, mucocutaneous rxn |
|
|
D Actinomycin |
Antitumor Abx MOA: Intercalation, inhibits Topoisomerase II |
|
|
Prednisone |
Hormonal Agent MOA: 11b hydroxysteroid dehydrogenase. lymphocytopenia to reduce lymphoid mass Tx: remission of ALL, NHL, Hodgkins |
|
|
Tamoxifen |
Hormonal Agent MOA: Selective Receptor Modulator, competitive agonist inhibitor of Estrogen. Lower affinity than estradiol. Ablate endogenous estrogen Tx: Breast |
|
|
Flutamide |
Hormonal Agent MOA: Antagonist at Androgen receptor, Testosterone antagonist Tx: Prostate Ca |
|
|
Bicalutamide |
Hormonal Agent MOA: Antagonist at Androgen receptor, Testosterone antagonist Tx: Prostate Ca |
|
|
Enxalutamide |
Hormonal Agent MOA: Antagonist at Androgen receptor, Testosterone antagonist Tx: Metastatic castration resistant Prostate CA (1st line) |
|
|
Leuprolide |
GNRH Agonist MOA: LH, FSH surge results in inhibition of LH, FSH release, decreased testosterone Tx: Prostate |
|
|
Goserelin |
GNRH Agonist MOA: LH, FSH surge results in inhibition of LH, FSH release, decreased testosterone Tx: Prostate |
|
|
Anastrozole |
Aromatase Inhibitor MOA: Inhibits conversion of estrogen from androgens Tx: Breast Ca |
|
|
Retrosole |
Aromatase Inhibitor MOA: Inhibits conversion of estrogen from androgens Tx: Breast Ca |
|
|
Exemestane |
Aromatase Inhibitor MOA: Inhibits conversion of estrogen from androgens - irreversible Tx: Breast Ca |
|
|
Bortezomib |
Proteasome inhibitor MOA: decrease IkB degredation to increase NFkB in cytosol --> apoptosis |
|
|
Bevacuzimab |
Monoclonal AB MOA: Binds VEGF. Localized inhibition of angiogenesis, and chemo, radiation. |
|
|
Rituzimab |
Monoclonal AB MOA: Binds CD 20 - ab dependent or complement lysis. Localized delivery of radiation, chemo |
|
|
Trastuzumab |
Monoclonal AB MOA: Binds HER2 - Ab dependent lysis. Localized delivery of radiation, chemo AE: Infusion Rxn, Cytokine release Tx: Breast |
|
|
Imatibab |
Tyrosine Kinase Inhibitor MOA: Inhibit PDGF and intracellular TK pathways Tx: CML |
|
|
Nilotinib |
Tyrosine Kinase Inhibitor MOA; Inhibits PDGF, intracellular TK pathways |
|
|
Bone Marrow sparing Drugs |
Cisplatin, Bleomycin, Vincristine |
